Dermatology Times

Dermatology Times is a weekly publication that serves as a key resource for dermatologists. It provides trustworthy, pertinent, and up-to-date coverage of the newest developments in the field of dermatology.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#226166

United States

#104819

Health/Medicine

#911

Traffic sources

Monthly visitors

Articles

Update: FDA Extends Review of Ruxolitinib Cream for Pediatric AD

1 week ago | dermatologytimes.com | Kaitlyn Bader

The US FDA has extended the review period of Incyte’s supplemental New Drug Application (sNDA) for ruxolitinib (Opzelura) cream for the treatment of pediatric patients aged 2 to 11 years with mild to moderate atopic dermatitis (AD).
HS Uncovered: Global Survey Highlights Patient Perspectives and Psychosocial Impact

1 week ago | dermatologytimes.com | Marie Bosslett

Global results from a recent survey have given clinical insights into the psychosocial impact hidradenitis suppurativa (HS) may have on patients across the world.1 “HS Uncovered” Burden of Disease Survey was created to help providers better understand patient journeys and perspectives with HS. The real-world, quantitative online survey included data from 656 patients.
FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid

1 week ago | dermatologytimes.com | Emma Andrus |Marie Bosslett

The US FDA announced today its approval of dupilumab (Dupixent; Regeneron Pharmaceuticals, Inc. and Sanofi) for adults with bullous pemphigoid (BP), marking the first and only targeted therapy for this patient population.1The approval is supported by positive data from the pivotal phase 2/3 LIBERTY-BP ADEPT study.2 The randomized, double-blind, placebo-controlled study assessed dupilumab in a cohort of 106 adults with moderate to severe BP over the course of 52 weeks.
Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD

1 week ago | dermatologytimes.com | Anabela Cardoso |Kaitlyn Bader

At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, Eli Lilly and Company presented new data from the phase 3b ADmirable trial (NCT05372419) of lebrikizumab (Ebglyss).1 The study is the first to evaluate lebrikizumab’s effectiveness and safety in adult and adolescent patients with pigmented skin and atopic dermatitis, as this population is typically underrepresented in clinical trials.
VALIANT Survey Shows High Rates of Depression in Patients with Vitiligo

1 week ago | dermatologytimes.com | Marie Bosslett

Data from the global Vitiligo and Life Impact Among International Communities (VALIANT) survey has revealed high rates of depression and depressive symptoms in patients with vitiligo.1 About 75% of surveyed patients had symptoms of depression.
Social Media Significantly Influences Attitudes, Behaviors Toward Skin Health

1 week ago | dermatologytimes.com | Brian Nowosielski

Social media was found to significantly impact the actions related to users’ skin health, according to a study published in the Journal of Medical Internet Research.1 Despite varied and inconclusive results regarding skin care promotion, researchers suggested that all skin-care interventions promoted on social be pretested and monitored for safe and effective use. “Social media browsing is the most popular online activity,” wrote authors of the study.
Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in AD Patients After 1 Year

1 week ago | dermatologytimes.com | Marie Bosslett

Positive retrospective study data has confirmed upadacitinib and abrocitinib's efficacy for moderate-to-severe atopic dermatitis (AD) in real-world settings.1 Safety and effectiveness have been proven in phase 3 clinical trials, but long-term, real-world results have been limited for these JAK inhibitors. For this trial, the AD database records of IRCCS Humanitas Research Hospital-Rozzano in Milan, Italy, were utilized. These electronic records were analyzed between January 2023 and December 2024.
Shifting the Paradigm in Infant Atopic Dermatitis Treatment with Roflumilast

1 week ago | dermatologytimes.com | Marie Bosslett |Mercedes E. Gonzalez |Mercedes González

“When I'm seeing a patient, an infant with atopic dermatitis (AD), I'd much prefer to have a conversation to discuss the side effect profile of roflumilast than having to discuss the side effect profile of a topical corticosteroid,” Mercedes E. Gonzalez, MD, told Dermatology Times.
German Study Explores the Emotional Impact of Work-Related CHE

1 week ago | dermatologytimes.com | Marie Bosslett

Researchers in Europe have investigated the emotional impact of work-related chronic hand eczema (CHE) on patients.1 They also evaluated the psychometric properties of the Atopic Eczema Score of Emotional Consequences (AESEC) and how it can be applied to CHE.
Journal Digest: June 18, 2025

1 week ago | dermatologytimes.com | Emma Andrus

Journal of Cosmetic Dermatology: A Case–Control Study Examining the Differences in Vitamin D Levels Between Individuals With Rosacea and Healthy IndividualsA case–control study conducted in Iran compared vitamin D levels between 31 patients with rosacea and 31 healthy controls. Although mean vitamin D levels were higher in the rosacea group (29.9 ng/mL) than in controls (24.5 ng/mL), the difference was not statistically significant.